News from bristol-myers squibb A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

11 Nov, 2014, 12:48 GMT Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel Ways to Cure Viral Diseases

The Partnering for Cure faculty of experts today announced the four recipients of awards for research proposals that will help to provide insights...


08 Apr, 2014, 10:07 BST European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme

Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research and facilitating greater...


11 Jun, 2013, 23:05 BST ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in First Long Term Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis[1]

The first and only two-year head-to-head study in adults with rheumatoid arthritis comparing two biologic drugs each on a background of methotrexate...


23 Apr, 2013, 11:35 BST High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection

This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option Investigational regimen involves three different...


07 Dec, 2012, 16:57 GMT Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic Myeloid Leukaemia in 15 European Countries

My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company...


07 Nov, 2012, 07:45 GMT Bristol-Myers Squibb Foundation Announces Centers Of Excellence Conference To Share Insights From Asia-Pacific Community Groups On Viral Hepatitis Management In Honour Of The 10-Year Anniversary Of Delivering Hope

The Bristol-Myers Squibb Foundation (the Foundation) and its partners today launched a Centers of Excellence Conference for Community Based Viral...


05 Nov, 2012, 07:45 GMT European Commission Approves Labelling Update for BARACLUDE® (entecavir) in Liver Transplant Patients with Chronic Hepatitis B

Bristol-Myers Squibb (NYSE: BMY) announced today that the European Commission (EC) has approved a BARACLUDE® (entecavir) Summary of Product...


29 Sep, 2012, 12:00 BST New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)

Long-Term Follow Up From Phase 3 Study (024) Demonstrated That 19.0 Percent of Treatment-Naïve Patients Who Received YERVOY at Investigational Dose...


26 Jul, 2012, 10:04 BST World Hepatitis Alliance (the Alliance), European Liver Patient Association (ELPA) and Bristol-Myers Squibb Announce Global Expansion of PATH B Programme on World Hepatitis Day to Address the Unmet Need in Resources for People Living with Chronic Hepatitis B

Patients and Professionals Acting Together for Hepatitis B (PATH B),http://www.pathb.com, provides the most comprehensive information and tools...


21 Oct, 2011, 09:00 BST "PATH B": A Comprehensive Support Programme in Europe for Patients Diagnosed With Chronic Hepatitis B Launched

Hepatitis B is one of the most common infectious diseases in the world, with 350 million people worldwide being chronically infected [1] - this...


20 Jun, 2011, 14:44 BST First-in-class Biologic Agent for Kidney Transplant Rejection Approved in Europe

European Commission approves NULOJIX® (belatacept), in combination with corticosteroids and a mycophenolic acid and an interleukin-2 receptor...


10 Jun, 2011, 17:20 BST Five-Year Follow-Up Data for SPRYCEL(R) (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib Mesylate[*]

Five-year follow-up results were presented today from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in...